Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?

Kidney Int. 2006 Apr;69(8):1293-5. doi: 10.1038/sj.ki.5000283.

Abstract

One reason for the inadequacy of current renoprotective therapy and the persistent poor renal prognosis in diabetic nephropathy is the large interindividual variation in response to treatment. Genetic as well as non-genetic factors are known to influence treatment efficacy. This Commentary summarizes the impact of the angiotensin-converting enzyme (ACE) insertion/deletion polymorphism in the ACE gene on initiation and progression of diabetic nephropathy.

Publication types

  • Comment

MeSH terms

  • Alleles
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Asian Continental Ancestry Group
  • Diabetic Nephropathies / drug therapy*
  • Gene Deletion*
  • Genetic Variation
  • Genotype*
  • Humans
  • Mutagenesis, Insertional*
  • Peptidyl-Dipeptidase A / genetics*
  • Polymorphism, Genetic
  • Prognosis
  • Survival Analysis

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Peptidyl-Dipeptidase A